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Introduction 
 
Sarcomas are malignant neoplasms of mesenchymal origin that comprise less than 1% of all 
cancers. They demonstrate aggressive biological behaviour, with the majority being locally 
invasive with significant potential for metastasis.1, 2 Sarcomas are generally divided into bone 
sarcomas (BS) and soft tissue sarcomas (STS).  
The overall annual incidence of BSs is 8/106. On average 38 BSs of the skull and facial 
skeleton are diagnosed in England annually. These account for 10% of all BS.1, 3  There is a 
male predilection and a bimodal age-specific distribution (second and third decade). 
Osteosarcomas, Ewing sarcoma and chondrosarcoma are the main histological subtypes.1 
The overall annual incidence of STSs is 30/106, with slight male predominance and the 
estimated median age at presentation is 65 years.1, 4, 5  On average 190 STSs of the head and 
neck region are diagnosed annually in England, accounting for 9% of all soft tissue 
sarcomas.4 They are histologically diverse with more than 50 described subtypes.1 
Of all adult sarcomas, only 5-15% occur in the head and neck region, with 5-year survival 
rates ranging from 27% to 84% in various studies.6-10  
The mainstay of treatment for BS is radical surgery, preceded by neo-adjuvant chemotherapy 
for high grade tumours. This treatment model is an extrapolation of the management applied 
to long bone sarcomas especially in limb-sparing surgery.11 The aim of neo-adjuvant 
chemotherapy in BS of the head and neck is two-fold: elimination of distant -lung 
predominantly- metastases and improvement of local control by reducing the need for large 
uninvolved soft tissue excision margins at the primary tumour site, which in many cases is 
difficult due to the complex anatomy of the head and neck region. The role of radiotherapy in 
head and neck BS is limited, with the exception of Ewing sarcomas. However, radiotherapy 
is appropriate for the management of residual disease in cases of positive resection margins, 
when surgical re-excision is not feasible, or when the lesion recurs in anatomically 
inaccessible areas.11  
Treatment for head and neck STS varies, depending on the specific histopathological type, 
grade and extent of the tumour. The threshold for using neo-adjuvant chemotherapy may be 
lower than in soft tissue sarcomas of the extremities, given the challenges of achieving local 
control. Radical radiotherapy is appropriate for similar indications as for BS.  Surgery is 
implemented in the management of STS in order to maximise the chances of disease control. 
The role of surgery in STS depends on the resectability of the disease. Its timing -prior or 
after radiotherapy- depends mainly upon the specific reconstructive aims and the healing 
potential of radiotherapy-treated tissues.   The management strategy is planned and reviewed 
within a specific sarcoma multidisciplinary setting with radiological, histopathological, 
oncological and surgical expertise.  
This paper reports a cohort of patients with head and neck sarcomas managed by the same 
surgical and medical team over a period of 13 years. We describe our experience and the 
evolution of surgical concepts adapted to the histopathological patterns and biological 
behaviour of these distinct groups of non-epithelial head and neck malignancies.  
  
Materials & Methods 
This study is in line with our institutional governance protocol. We analysed the records of 
head and neck oncology patients treated between 1997-2010. In this 13 years period the three 
senior authors (NK, LN and JW) consistently managed all head and neck sarcoma patients.   
High grade BS were routinely considered for neo-adjuvant chemotherapy using standard 
regimens in the absence of significant co-morbidities. In most cases the goal was to complete 
chemotherapy prior to the definitive surgical resection with the response assessment 
undertaken using PET-CT.12 For patients with Ewing sarcomas, the use of radiotherapy 
instead of surgery was considered on the basis of individual tumour characteristics and 
response. Patients with chondrosarcomas were treated surgically. Patients with STS 
underwent primary resection followed by post-operative radiotherapy depending on resection 
histology. 
All statistical analysis was performed using the statistical software package SPSS 12.0 (IBM, 
New York, USA). Survival estimates (Overall Survival and Event-free survival) have been 
calculated using the Kaplan-Meier method.13 Complete follow-up data was available for 101 
patients. The follow-up was calculated in months. For the event-free survival estimates, 
recurrence, metastasis or disease-specific death have been classified as ‘event’. The log-rank 
test was used for uni-variate survival comparison.14 In chi-square analysis p values <0.1 were 
considered significant.   
  
Results  
A total of 107 patients with head and neck sarcomas were identified.  The histopathological 
subtypes of bone and soft tissue sarcomas are illustrated in Table 1. 
 
Bone Sarcomas 
Fifty-four patients had BS (33 males, 21 females, male/female ratio: 1.6:1). The mean age 
was 41 years (range 9-81 years). Fifty cases were primary localised bone sarcomas, whereas 
two were recurrent from previously elsewhere treated tumours, one was already metastatic at 
presentation and the fourth was a secondary deposit from a non head-neck sarcoma (these 
cases were not included in the subsequent survival analysis).  
Bone sarcomas predominantly arose in the mandible (29/54, 54%), followed by the maxilla 
(19/54, 34%), whereas six cases occurred in extragnathic locations (6/54, 11%), namely one 
in the frontal bone, one in the sphenoid bone, one sinonasal and three chondrosarcomas 
arising from the laryngeal structures. The majority of the tumours (49 out of 54, 91%) were 
high grade. Eight osteosarcomas were radiation induced. 
Neoadjuvant chemotherapy was used in 28 osteosarcomas and in the 5 cases of Ewing’s 
sarcomas followed by surgery (Figure 1). Twenty-five mandibulectomies and 21 
maxillectomies were performed, with the type and extent of resections is presented in Table 
2.15, 16  
Four cases comprised en bloc resections of both hemi-mandible and maxilla in the context of 
compartmental excision along with lateral access and base of skull clearance.  
In osteosarcomas when histopathology reported involved resection margins, re-excision was 
performed. Out of 39 surgically treated osteosarcomas where histological data were retrieved, 
35 were completely excised. Three mandibular osteosarcoma cases with tumour dimensions 
above 8cm were extending into the cranial base were the excision margins were reported 
involved. The fourth case was a radiation induced sarcoma, with disease extending along the 
totality of the mandible and a substantial part of the floor of the mouth. 
A significant observation was noted early on bone sarcomas centred at the retromolar region 
extending proximally to the vertical ramus of the mandible. Although Magnetic Resonance 
Imaging (MRI) is considered to be the gold standard in assessing bone marrow invasion, in 
two cases the extent of the disease in the condylar area was grossly underestimated. In those 
cases the histopathology analysis demonstrated florid disease infiltration of the condylar head 
without exceeding the end plate of the cortex causing no cortical alterations and therefore no 
visible imaging changes (Figure 2). It is our policy now to perform hemi-mandibulectomy 
with condylar disarticulation in osteosarcomas that extend into the mandibular ramus. We 
have performed 12 condylar disarticulation resections, that were subsequently ratified by the 
histological analysis.    
The majority of mandibulectomy defects were reconstructed with vascularized composite 
flaps (15 fibulas, 4 DCIA flaps). In three cases no bone reconstruction was attempted due to 
substantial co-morbidities and the composite defect was closed using myocutaneous pedicled 
latissimus dorsi flaps. One patient aged 9 years was reconstructed with a costochondral graft.  
The maxillectomy defects were reconstructed primarily with free flaps (three fibulas and one 
DCIA), the rest been obturated. For bi-maxillary defects one chimeric scapula, one DCIA and 
two large composite fibula flaps were used.   
Radiotherapy (IMRT) was delivered in 10 cases; in four for positive margins in unresectable 
areas and in the rest for palliation. 
Eight low grade chondrosarcomas were operated. In three laryngeal cases with slow growth 
radical surgery was avoided and tumours were incompletely excised.  
Follow-up was recorded for 51 bone sarcoma patients (mean 48 months).  
The 2- and 5-year overall survival (OS) estimates were 91% and 73% (data available for 
n=51). The 2- and 5-year event-free survival rates for BSs were 66% and 49% (Figure 3). 
 
Soft tissue sarcomas   
Fifty-three patients had STSs (28 male, 25 female, male/female ratio: 1.1:1). Mean age was 
43 years (range 7-86 years). Six patients with soft tissue sarcomas had already developed 
metastatic disease at the time of their presentation. Information about tumour grade was not 
available for 19 tumours. Out of 34 tumours where grade data was available, 26 (76%) were 
high grade and 8 (24%) were low grade. Six tumours were radiation induced. Five patients 
had distant metastatic disease at the time of the diagnosis. Two of these cases were 
rhabdomyosarcomas, one myxofibrosarcoma, one malignant peripheral nerve sheath tumour 
and one angiosarcoma.  
The site distribution of soft tissue sarcomas was widely dispersed. We utilised a site-specific 
classification based on the anatomical landmarks set by Roon, Christensen17 and Ohngren18 
to divide the head and neck region in four zones (Figure 4):  
I) High - above the angle of the mandible. This area is further divided by Ohngren’s line 
(medial canthus to angle of mandible) into the region Ia antero-inferiorly, which encompasses 
the facial anatomical boundary, and Ib postero-superiorly, which contains the skull base, 
infratemporal, pterygopalatine and retrobulbar spaces.  
II) Middle - between the angle of the mandible and the lower border of the cricoid cartilage.  
III) Low – below the cricoid cartilage. 
The distribution pattern of the tumours’ epicentres is illustrated in Figure 4. 
Neoadjuvant chemotherapy followed by surgery was used in 20 out of 53 STSs, mainly for 
rhabdomyosarcomas and high grade sarcomas for which resection was anticipated to result in 
marginal or involved margins. Surgery was employed in 39 cases .  
The tumours were resected by wide compartmental excision. For tumours sited in zone I, 9 
mandibulectomies and 6 maxillectomies were performed, including 3 cases were en bloc 
mandibulo-maxillary resections along with skull base clearance were performed (Table 2). 
Sixteen free flap reconstructions were performed.  
Clear surgical margins were achieved in 25/39 (64%) of the cases (Figure 4). Clearance was 
achieved in 72% of zone Ia, 33% of zone Ib (59% in Zone I in total), 80% of zone II and 50% 
of zone III tumours. The difference in tumour clearance between zone Ia and Ib was 
significant. In zone III 3/5 of tumours were unresectable due to extension into the thoracic 
cavity with subsequent invasion of vital structures.  
Radiotherapy was delivered in a total of 29 cases. In 11 out of 43 operated cases radiotherapy 
was administered for positive margins in unresectable disease.     
The 2- and 5-year overall survival rates were 67% and 56% respectively (data available for 
n=50) (Figure 5). The 2- and 5-year event-free survival rates were 54% and 47%, 
respectively. 
The survival rates of all the cases divided by histological type are demonstrated on Table 3.  
 
 
 
 
 
  
Discussion 
Sarcomas are a widely heterogeneous group of malignant tumours. Their rarity in the head 
and neck region accounts for the lack of consistency in the literature regarding their 
management and outcomes. There are no randomised controlled studies and the existing 
metanalyses provide controversial results.19, 20  
In this study, we report the outcomes of a large BS and STS series. Mean age at presentation 
and site distribution were consistent with those published in the literature.21, 22 Soft tissue 
sarcomas series are largely variable due to the rarity, diversity and heterogeneity of these 
tumours.23  
In our series, the majority of bone (91%) and soft tissue (76%) sarcomas were high-grade. 
The incidence of high-grade tumours in the head and neck region is reported to vary between 
56% and 79% in osteosarcomas.24, 25  
Surgery for sarcomas is based on the principles of oncological ablative and reconstructive 
surgery, however distinct factors related to the disease characteristics and the usage of neo-
adjuvant chemotherapy dictate additional variables in the concept of their excision. The 
mesenchymal origin of these tumours in contrast with the majority of the head and neck 
epithelial-derived cancers, predisposes to a different pattern of disease spread and potentially 
different extent of cancellous bone infiltration (Supplementary data).  
The importance of surgical resection of BSs with clear margins has been emphasized in the 
paper of Chen et al.26 Regarding the target resection margin, some groups advocate a 3cm 
macroscopic margin.8 In conventional trunk and extremities osteosarcomas, most studies 
suggest that a 2cm macroscopic margin is adequate.27, 28 This has been reinforced by the 
input of neoadjuvant chemotherapy, which potentially eliminates microsatellite tumour 
deposits that extend beyond the primary tumour.29, 30 An important key-point is, that where 
neoadjuvant treatment (chemotherapy) has been employed, the resection should be planned 
based on the pre-treatment scans. Surgical planning based solely on post-neo-adjuvant 
treatment imaging, especially in cases with radiologic good response, may be misleading due 
to the frequently encountered partial and certainly non-concentric pattern of tumour 
“shrinkage”.  
A simplistic geometrical approach of ‘measuring’ centimetres around the tumour in the 
anatomically complex head and neck region is not applicable. Our experience has shown that 
sufficient margins are only achieved when performing a wide ‘compartmental’ excision, 
aiming at large bony margins with concomitant complete excision of the surrounding soft 
tissue envelope. The removal of the involved anatomical compartment has to be performed in 
a fashion wide enough to encompass all potentially involved structures taking into account 
the potential of bone marrow involvement beyond the radiological reported ‘margins’  
(Figure 2). To this end frank hemi-mandibulectomy and even condylar disarticulation have to 
be considered when the tumour, especially a high-grade osteosarcoma, extends to the 
mandibular ramus. Preservation of a small condylar segment may have little to offer in the 
subsequent reconstruction but most importantly can inhibit access to the base of skull when 
this is needed (i.e. infratemporal fossa involvement) jeopardising soft tissue clearance. In our 
experience mandibular reconstruction with composite fibula facilitates satisfactory mouth 
opening, while –not uncommonly- we have noticed that preservation of a small condylar 
segment may result in “late” anterior-medial displacement due to lateral pterygoid muscle 
traction. In this reported series of osteosarcomas, surgical clearance was achieved in 85% of 
the cases.  
In soft tissue sarcomas the aim is a macroscopic margin of 1-3cm where possible.31 The 
importance of the marginal status in the disease free and overall survival has been clearly 
demonstrated.9, 23, 31 It is widely accepted that surgical clearance in STSs is more difficult to 
achieve.9, 10, 23, 32 Reasons are the biological aggressiveness of soft tissue sarcomas and the 
pattern of infiltration into the neighbouring vital neurovascular structures limiting their 
amenability for radical resection. Surgical clearance in our series of soft tissue sarcomas was 
achieved in 25/39 (64%) of our cases. The experience gained from this series suggests that 
tumours arising within zone Ib or large tumours form adjacent areas extending into it are 
particularly difficult to clear. Eleven out of 14 incompletely excised head and neck soft tissue 
sarcomas were in zone I (6 arising within zone Ib and 5 extending from Ia into zone Ib). This 
site-specific classification especially for soft tissue sarcomas can serve as a potential 
prognosticator aiding the decision-making algorithm when initially planning the management 
of these patients. In tumours confined in zone Ia surgery plays a pivotal role, whereas in zone 
Ib tumours poor surgical outcomes may be encountered. 
In this series the overall survival estimate for BSs (n=51) reached 91% at 2 years and 73% at 
5 years, whilst for STSs (n=50) 67% at 2 years and 56% at 5 years, respectively. 
Corresponding studies report overall survival rates of 84% at 2 years and 61% at 5 years for 
mixed bone and soft tissue tumours10, 79% at 2 years and 74% at 5 years22 and 63% at 5 
years21 for BSs, and 57% at 5 years for STSs (n=50).33 In our series the bone sarcomas 
displayed significantly better overall survival probability (p=0.0029, Log-rank test) 
comparing to soft tissue sarcomas.  
Although the outcomes of this series are comparable to the majority published in the 
literature, we believe that comparisons of survival estimates among different studies are 
difficult, due to the heterogeneity of histopathological types, the variations in the composition 
of studied populations and the diversities in the follow-up time spans. For example, the 
survival outcomes reported in our series, are the cumulative ones for all the patients managed 
in our centre, including cases with secondary or metastatic tumours. Interestingly, in our 
cohort we included 14 cases of radiation-induced tumours. Radiation-induced sarcomas are 
associated with significantly poorer outcome than that of the stage-matched irradiation-
independent counterpart sarcomas, with overall 5-year survival rates as low as 25%. The 
attributing factors include delay in diagnosis, biological aggressiveness, chemotherapy 
resistance and the limitation in treatment options, especially the ineligibility for radiotherapy 
and the technical difficulties in obtaining clear margins because of frequent proximity of the 
tumours to major neurovascular structures. 34-36  
As a retrospective analysis, the current study is subjected to limitations. In this series the 
wide histopathological diversity, especially with the soft tissue sarcomas comprising a 
conglomerate of heterogeneous subtypes and anatomical locations, did not allow stratified 
multi-variate analysis. 
A meta-analysis including all series published by different centres, or even randomised 
clinical trials will be useful to address fundamental questions in the field of head and neck 
sarcomas management. 
 
Conclusions 
Surgery has to consider the degree of bone marrow infiltration and aim for a wide 
‘compartmental’ excision with large bony margins and sufficient surgical clearance of the 
soft tissue envelope in the surgical treatment of bone sarcomas. Soft tissue sarcomas are 
histologically extremely diverse and surgery should be the primary modality of treatment in 
relatively small disease burden or cases of low/ moderate grading.   
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Figure legends 
Figure 1. MRI scan of mandibular osteosarcoma. a. Prior to neoadjuvant chemotherapy; i. 
Coronal slice ii. Axial view. b. Post-6 cycles of MAP chemotherapy; i. Coronal slice. ii. 
Axial view. 
Figure 2. Discrepancy between extent of tumour marrow invasion as seen in: a. histological 
specimen of the condylar head. b. MRI coronal sections of the same region 2 weeks 
preoperatively. 
Figure 3. Kaplan-Meier survival estimates for bone sarcomas (n=51). a. Overall survival. b. 
Event free survival estimates. 
Figure 4. Site-specific classification for soft tissue sarcomas in relation to tumour clearance. 
Green: completely excised tumours. Red: Tumours excised with one or more positive 
margins. Blue: Non-operated tumours. 
Figure 5. Kaplan-Meier survival estimates for soft tissue sarcomas (n=50).  a. Overall 
survival. b. Event free survival estimates. 
Figure 6. Schematic presentation of tumour invasion pathway in the mandible. a. Epithelial 
tumour arising from mucosa infiltrating through the cortex into the medullary space 
(Out→In). b. Osteosarcoma arising from the medullary space infiltrating the bone marrow 
and penetrating through the bone into the soft tissues (In→Out). 
  
Table 1. Head and neck sarcoma cases breakdown. Histopathological classification and 
treatment modalities. *MPNST: malignant peripheral nerve sheath tumour 
HEAD	&	NECK	SARCOMAS	
NUMBER	
OF	
CASES	
SURGERY		
NEOADJUVANT	
CHEMOTHERAPY	 RADIOTHERAPY		
BONE	SARCOMAS	 54		 49/53	 33/53	 10/53		
Osteosarcomas	 41		 37/41	 28/41		 5/41		
Ewing’s	sarcomas	 5		 4/5		 5/5		 3/5	
Chondrosarcomas	 8		 8/8		 0/8	 2/8		
	 	 	 	 	
SOFT	TISSUE	SARCOMAS	 53		 43/53	 20/53	 29/53	
Rhabdomyosarcoma	 12		 8/12	 4/12	 6/12	
Spindle	cell	sarcoma	 6		 6/6	 2/6	 2/6	
Myxofibrosarcoma	 5		 3/5	 1/5	 4/5	
Synovial	sarcoma	 3		 3/3	 1/3	 3/3	
Neurofibrosarcoma	(MPNST*)	 4		 4/4	 0/4	 2/4	
Myofibrosarcoma	 3		 2/3	 0/3	 0/3	
Leiomyosarcoma	 5		 4/5	 2/5	 4/5	
Liposarcoma	 2		 2/2	 0/2	 1/2	
Dermatofibrosarcoma	 2		 2/2	 1/2	 0/2	
Angiosarcoma	 1		 0/1	 0/1	 1/1	
Alveolar	soft	part	 1		 1/1	 1/1	 1/1	
Undifferentiated/Pleomorphic	 9	 8/9	 3/9	 5/9	
	
	 	
Table	2.	Extent	of	mandibulectomies	and	maxillectomies.	
	
	
	 	
MANDIBULECTOMIES	 	 MAXILLECTOMIES	
Bone	Sarcomas	
N=25	 	 N=21	
HLCL	 3	 	 Limited	 11	
HLC	 3	 	 Subtotal	 8	
HL	 8	 	 Total	 2	
LC	 6	 	 Radical	(incl.	orbit)	 0	
L	 4	 	 	 	
C	 1	 	 	 	
	 	 	 	 	
Soft	tissue	sarcomas	
N=	9	 	 N=7	
HL	 4	 	 Limited	 0	
LCL	 1	 	 Subtotal	 3	
LC	 1	 	 Total	 2	
L	 3	 	 Radical	(incl.	orbit)	 2	
	 	 	 	 	
The	mandibulectomies	have	been	classified	according	to	Boyd	et	al.,	where	H=Hemimandible	including	the	condyle	(disarticulation),	
L=Lateral	 (body)	of	mandible	and	C=Central	anterior	segment	encompassing	the	symphyseal	 region.	The	maxillectomies	have	been	
classified	according	to	Spiro	et	al.	
		 	
		 	
		 	
		 	
		 	
		 	
	
